Maternal Hyperoxygenation for Prenatal Risk Stratification of Pulmonary Venous Obstruction in Total Anomalous Pulmonary Venous Return - Scorecard - MDSpire
Clinical Scorecard: Prenatal Risk Assessment of Pulmonary Venous Obstruction in Total Anomalous Pulmonary Venous Return through Maternal Hyperoxygenation
At a Glance
Category
Detail
Condition
Total Anomalous Pulmonary Venous Return (TAPVR)
Key Mechanisms
Maternal hyperoxygenation enhances fetal pulmonary blood flow and may reveal pulmonary venous obstruction.
Target Population
Fetuses diagnosed with TAPVR
Care Setting
Obstetric screening and fetal echocardiography
Key Highlights
Pulmonary venous obstruction affects 25-50% of TAPVR cases.
Maternal hyperoxygenation can enhance perinatal planning for fetuses with congenital heart disease.
Doppler thresholds for assessing pulmonary venous obstruction may be limited by baseline fetal hemodynamics.
MHO testing may reveal fixed anatomic obstruction in the pulmonary venous pathway.
Initial experience indicates MHO testing correlates with neonatal clinical outcomes.
Guideline-Based Recommendations
Diagnosis
Utilize fetal echocardiography and Doppler assessment for prenatal TAPVR diagnosis.
Incorporate maternal hyperoxygenation to assess postnatal obstruction risk.
Management
Plan delivery at a tertiary care center for neonates with concerning Doppler findings.
Monitoring & Follow-up
Monitor pulmonary vasoreactivity and Doppler measurements during MHO.
Risks
Neonates with severe pulmonary venous obstruction may experience rapid respiratory compromise.
Patient & Prescribing Data
Fetuses with prenatal TAPVR diagnoses
MHO testing may guide delivery planning and postnatal intervention.
Clinical Best Practices
Conduct comprehensive fetal echocardiography at mid-gestation.
Perform MHO testing at 34-36 weeks’ gestation to assess pulmonary venous flow.
